From Pandemic to Pipeline: What’s Next for Moderna?
GEN Edge discusses Moderna’s strengths and challenges in COVID-19 and beyond with Karen Andersen, CFA, Morningstar senior strategist, biotechnology.
GEN Edge discusses Moderna’s strengths and challenges in COVID-19 and beyond with Karen Andersen, CFA, Morningstar senior strategist, biotechnology.
A new study shows that an inhibitor called ESI1 could potentially treat multiple sclerosis and other conditions associated with demyelination.
A team of researchers sought to determine the efficacy of psilocybin as an antidepressant compared with placebo or non-psychoactive drugs.
Novartis plans to acquire Mariana Oncology for up to $1.75 billion, further expanding the buyer’s radiopharmaceutical and cancer pipelines.
Future research could identify drugs that can target this newfound brain circuit to help treat a vast range of immune disorders and diseases.
Disrupting the gut microbiome of male mice increases the probability that their offspring are born with low weight and will die prematurely.
Vaccine harnesses multi-lamellar LP aggregates (LPA) that can simultaneously function as vaccines and as immunomodulating agents.
When asked about the most challenging part of turning TILs into therapies, it is expanding a sample into billions of cells.
Disrupting the gut microbiome of male mice increases the probability that their offspring are born with low weight and will die prematurely.
NIIMBL’s mission is to accelerate biopharmaceutical innovation, support development of manufacturing standards, and boost workforce skills.
The formation and dissociation of the supramolecular drug complex are controlled by the binding of synthetic peptide nucleic acids (PNAs).